| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Institut Nationale de la Santé et de la Recherche Médicale, Unité 479, Faculté Xavier Bichat, Paris, France;
Service de Rheumatologie, Centre Hospitalo-Universitaire Xavier Bichat, Paris, France;
Service d’Anatomie Pathologique, Centre Hospitalo-Universitaire Xavier Bichat, Paris, France;
Imclone Systems, Inc., New York, NY 10014; and
¶
SUGEN, Inc., South San Francisco, California 94080
It was recently shown that vascular endothelial growth factor (VEGF), a growth factor for endothelial cells, plays a pivotal role in rheumatoid arthritis. VEGF binds to specific receptors, known as VEGF-RI and VEGF-RII. We assessed the physical and histological effects of selective blockade of VEGF and its receptors in transgenic K/BxN mice, a model of rheumatoid arthritis very close to the human disease. Mice were treated with anti-mouse VEGF Ab, anti-mouse VEGF-RI and -RII Abs, and an inhibitor of VEGF-RI tyrosine kinase. Disease activity was monitored using clinical indexes and by histological examination. We found that synovial cells from arthritic joints express VEGF, VEGF-RI, and VEGF-RII. Treatment with anti-VEGF-RI strongly attenuated the disease throughout the study period, while anti-VEGF only transiently delayed disease onset. Treatment with anti-VEGF-RII had no effect. Anti-VEGF-RI reduced the intensity of clinical manifestations and, based on qualitative and semiquantitative histological analyses, prevented joint damage. Treatment with a VEGF-RI tyrosine kinase inhibitor almost abolished the disease. These results show that VEGF is a key factor in pannus development, acting through the VEGF-RI pathway. The observation that in vivo administration of specific inhibitors targeting the VEGF-RI pathway suppressed arthritis and prevented bone destruction opens up new possibilities for the treatment of rheumatoid arthritis.
This article has been cited by other articles:
|
|
 |
|
  N. Rajasekaran, S. Solomon, T. Watanabe, H. Ohtsu, M. Gajda, R. Brauer, and H. Illges Histidine decarboxylase but not histamine receptor 1 or 2 deficiency protects from K/BxN serum-induced arthritis Int. Immunol., November 1, 2009; 21(11): 1263 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Ryu, T. Cho, H. B. Choi, Y. T. Wang, and J. G. McLarnon Microglial VEGF Receptor Response Is an Integral Chemotactic Component in Alzheimer's Disease Pathology J. Neurosci., January 7, 2009; 29(1): 3 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shahrara, A. E. I. Proudfoot, C. C. Park, M. V. Volin, G. K. Haines, J. M. Woods, C. H. Aikens, T. M. Handel, and R. M. Pope Inhibition of Monocyte Chemoattractant Protein-1 Ameliorates Rat Adjuvant-Induced Arthritis J. Immunol., March 1, 2008; 180(5): 3447 - 3456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Mould, P. Scotney, S. A. Greco, N. K. Hayward, A. Nash, and G. F. Kay Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model Rheumatology, March 1, 2008; 47(3): 263 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Inoue, T. Kondo, K. Kobayashi, M. Aoki, Y. Numaguchi, M. Shibuya, and T. Murohara Therapeutic Angiogenesis Using Novel Vascular Endothelial Growth Factor-E/Human Placental Growth Factor Chimera Genes Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Murakami, S. Iwai, S. Hiratsuka, M. Yamauchi, K. Nakamura, Y. Iwakura, and M. Shibuya Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages Blood, September 15, 2006; 108(6): 1849 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Girardi, D. Yarilin, J. M. Thurman, V. M. Holers, and J. E. Salmon Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction J. Exp. Med., September 4, 2006; 203(9): 2165 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Webster, E. H. Ekland, L. M. Agle, S. Chyou, R. Ruggieri, and T. T. Lu Regulation of lymph node vascular growth by dendritic cells J. Exp. Med., August 7, 2006; 203(8): 1903 - 1913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Salvador, R. Sanmarti, B. Gil-Torregrosa, A. Garcia-Peiro, J. R. Rodriguez-Cros, and J. D. Canete Synovial vascular patterns and angiogenic factors expression in synovial tissue and serum of patients with rheumatoid arthritis Rheumatology, August 1, 2006; 45(8): 966 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tussiwand, N. Onai, L. Mazzucchelli, and M. G. Manz Inhibition of Natural Type I IFN-Producing and Dendritic Cell Development by a Small Molecule Receptor Tyrosine Kinase Inhibitor with Flt3 Affinity J. Immunol., September 15, 2005; 175(6): 3674 - 3680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Huber, M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, H.-J. Grone, J. Debus, K. E. Lipson, and A. Abdollahi Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy Cancer Res., May 1, 2005; 65(9): 3643 - 3655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-A. Yoo, D.-G. Bae, J.-W. Ryoo, H.-R. Kim, G.-S. Park, C.-S. Cho, C.-B. Chae, and W.-U. Kim Arginine-Rich Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Hexapeptide Inhibits Collagen-Induced Arthritis and VEGF-Stimulated Productions of TNF-{alpha} and IL-6 by Human Monocytes J. Immunol., May 1, 2005; 174(9): 5846 - 5855. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
